Company Overview and News

 
DCG(I) bans 344 drugs constituting fixed dose combinations, but will it hold?

2016-03-21 financialexpress
Abhijeet Das, Senior Associate, Singhania and Partners, opines that there are multiple fronts on which the aggrieved pharma companies can contest the ban

 
Inhalation and Nasal Spray Generic Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023

2016-03-01 prnewswire
NEW YORK, Feb. 29, 2016 /PRNewswire/ -- This report on the inhalation and nasal spray generic drugs market studies...

 
BAATZ v. COLUMBIA GAS TRANSMISSION LLC

2016-02-27 caselaw.findlaw
FindLaw's searchable database of United States Sixth Circuit decisions since

 
Neutral rating on Sun Pharma: Q3FY16 driven by Taro

2016-02-21 financialexpress
Strong performance of Taro was the key contributor during the quarter. Higher other income and lower tax rate resulted in PAT being 4% higher than our estimates.

 
Alstom, Cipla among 10 FDI proposals worth ₹607 crore cleared

2016-02-15 thehindubusinessline
8 proposals deferred, 5 rejected by Foreign Investment Promotion Board

 
Corporate Results 2016

2016-02-10 freepressjournal.in
MUMBAI : Indian Bank is expected to report a 14% year-on-year fall in net profit for Oct-Dec at 2.38 bln rupees due to a likely rise in provisions,according to the average of the estimates of four brokerage houses.The public sector bank is scheduled to announce its earnings for Oct-Decon Thursday.Sequentially, the bottomline is seen falling 36%.”Expect 17% YoY growth in opex (operational expenditure), largely on a lower base (-5% YoY in the year-ago period)… elevated credit costs areexpected to result in PAT de-growth of (nearly) 35% YoY.

 
Cipla Q3 net profit rises 4.68% to Rs 343 cr

2016-02-10 business-standard
Net sales during the period under review stood at Rs 3,027.26 crore, up 15.33%.

 
Cipla, Ambuja Cement, Kalpataru Power and GMR Infra: Check out the expectations

2016-02-10 indiainfoline
Cipla Ltd, one of the leading drug makers in India, will announce its financial results on February 10. IIFL forecasts the company’s net revenue for Q3 FY16 to increase to Rs. 3,403 crore, growing at a rate of 23.1% yoy; however, it is likely to drop 1.4% qoq.

 
Y.K. Hamied to up stake in Cipla by 5%

2016-01-21 livemint
Hamied, who holds 15.54% in Cipla, will increase his stake to 20.76% once the proposal is approved

 
Cipla gets CCI nod for investment by FIL Capital

2016-01-21 moneycontrol
The Competition Commission of India has granted approval to the proposed investment by FIL Capital Investments (Mauritius) II Limited in Cipla Health Limited, subsidiary of the company, Cipla Ltd said in a regulatory filing. ..

 
Natco signs pact to make and sell hepatitis-C drug in 112 countries

2016-01-21 livemint
Natco signed a pact with Medicines Patent Pool and Bristol-Myers Squibb to make and sell identical version of Daclatasvir, a drug used to treat hepatitis C

 
Pharma Packaging Trends in 2016

2016-01-20 financialexpress
Securing the supply chain, environmental sustainability and updation of technology infrastructure will be the buzzwords. By Usha Sharma

 
Emerging Markets: Health Care and Pharma

2016-01-14 nasdaq
Join the NASDAQ Community today and get free, instant access to portfolios, stock ratings, real-time alerts, and more!

 
Cipla sets up 6-member leadership team

2016-01-07 business-standard
Drug major Cipla today announced the creation of a 6-member 'Management Council' that will be the apex executive leadership team for the company. Headed by Subhanu Saxena, Managing Director & Global Chief Executive Officer, the council will

1
Cipla sets up 6-member leadership team

2016-01-07 moneycontrol
This is part of the company's ongoing transformation journey to simplify decision making and improve operational excellence, Cipla Ltd said in a statement. ..

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...